GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Lumateperone capsules (Caplyta)

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Return to full drug recordRead selected sourcesHow to use this review

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Lumateperone capsules (Caplyta) - selected U.S. label sections

Product / population
CAPLYTA oral capsules.
Renal method
eGFR in mL/min/1.73 m2; single-dose PK study
Source revision
Revision not captured; retrieval date is not the revision date.
Retrieved
2026-09-05
Local review status
Local label summary; independent clinical review pending. Not a two-source validated protocol.
Official

Lumateperone capsules (Caplyta) - selected U.S. label sections

Open original reference

U.S. product labeling / DailyMed · CAPLYTA oral capsules.

Renal method: eGFR in mL/min/1.73 m2; single-dose PK study
Source date: Revision not captured; retrieval date is not the revision date.
Retrieved: 2026-09-05

Local label summary; independent clinical review pending. Not a two-source validated protocol.

Renal pharmacokinetic study

The selected label describes a single 14 mg dose in patients with varying renal function. Moderate impairment (eGFR 30-59) did not change measured exposure. In severe impairment (eGFR at or below 29), the reported mean AUC and peak-concentration ratios versus normal renal function were 1.5 and 1.4.

RDM32-lumateperone-caplyta-1 · Source locator: 12.3, Table 8

Interpretation limit

These are pharmacokinetic observations, not instructions to divide the clinical dose by an exposure ratio. This entry does not create a renal or dialysis dosing schedule.

RDM32-lumateperone-caplyta-2 · Source locator: 12.3, Table 8

Source-specific limits

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db730b06-6351-47fd-8183-e61e61bbead5
Retrieved
2026-09-05
DailyMed Set ID
db730b06-6351-47fd-8183-e61e61bbead5
Renal-function method
eGFR in mL/min/1.73 m2; single-dose PK study
Source date/version
Revision not captured; retrieval date is not the revision date.
Hash meaning
SHA-256 identifies this local summary, not original SPL XML or a label PDF.
Local summary SHA-256
e2e6b8ba08f615aeaaaabfc9afc2c5e2135f4cbf3ea87e6c81a9d935bb0a96ad

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=lumateperone-caplyta&s1=RDM32-label-lumateperone-caplyta&h1=4885b54adc364a18644f76d64592d2c42d4085378183381729f657ea74c01ccd